Shares Outstanding Shares Outstanding n/a Close	135.1M
Shares Change (YoY) Shares Change (YoY) n/a Close	-3.97%
Shares Change (QoQ) Shares Change (QoQ) n/a Close	-4.08%
Owned by Institutions (%) Owned by Institutions (%) n/a Close	40.4%
Shares Floating Shares Floating n/a Close	120.13M
Failed to Deliver (FTD) Shares Failed to Deliver (FTD) Shares n/a Close	5,544
FTD / Avg. Volume FTD / Avg. Volume n/a Close	0.46%

Short Selling Information

The latest short interest is 10.5M, so 7.77% of the outstanding shares have been sold short.

Short Interest Short Interest n/a Close	10.5M
Short % of Shares Out Short % of Shares Out n/a Close	7.77%
Short % of Float Short % of Float n/a Close	8.49%
Short Ratio (days to cover) Short Ratio (days to cover) n/a Close	7.77

Valuation Ratios

The PE ratio is 223.34 and the forward PE ratio is 10.76. Aurinia Pharmaceuticals's PEG ratio is -2.08.

PE Ratio PE Ratio n/a Close	223.34
Forward PE Forward PE n/a Close	10.76
PS Ratio PS Ratio n/a Close	5.46
Forward PS Forward PS n/a Close	3
PB Ratio PB Ratio n/a Close	3.4
P/FCF Ratio P/FCF Ratio n/a Close	29.13
PEG Ratio PEG Ratio n/a Close	-2.08

Financial Ratio History

Enterprise Valuation

Aurinia Pharmaceuticals has an Enterprise Value (EV) of 1.28B.

EV / Sales EV / Sales n/a Close	5.45
EV / EBITDA EV / EBITDA n/a Close	40.36
EV / EBIT EV / EBIT n/a Close	28.85
EV / FCF EV / FCF n/a Close	29.03

Financial Position

The company has a current ratio of 4.57, with a Debt / Equity ratio of 0.21.

Current Ratio Current Ratio n/a Close	4.57
Quick Ratio Quick Ratio n/a Close	4.17
Debt / Equity Debt / Equity n/a Close	0.21
Debt / EBITDA Debt / EBITDA n/a Close	2.5
Debt / FCF Debt / FCF n/a Close	1.8
Interest Coverage Interest Coverage n/a Close	-0.97

Financial Efficiency

Return on Equity is 1.52% and Return on Invested Capital is -0.77%.

Return on Equity Return on Equity n/a Close	1.52%
Return on Assets Return on Assets n/a Close	1.04%
Return on Invested Capital Return on Invested Capital n/a Close	-0.77%
Revenue Per Employee Revenue Per Employee n/a Close	$1,808,715.38
Profits Per Employee Profits Per Employee n/a Close	$44,246.15
Employee Count Employee Count n/a Close	130
Asset Turnover Asset Turnover n/a Close	0.43
Inventory Turnover Inventory Turnover n/a Close	0.72

Taxes

Income Tax Income Tax n/a Close	1.7M
Effective Tax Rate Effective Tax Rate n/a Close	22.77%

Stock Price Statistics

The stock price has increased by 46.75% in the last 52 weeks. The beta is 1.16, so Aurinia Pharmaceuticals's price volatility has been higher than the market average.

Beta Beta n/a Close	1.16
52-Week Price Change 52-Week Price Change n/a Close	46.75%
50-Day Moving Average 50-Day Moving Average n/a Close	7.99
200-Day Moving Average 200-Day Moving Average n/a Close	7.96
Relative Strength Index (RSI) Relative Strength Index (RSI) n/a Close	51.98
Average Volume (20 Days) Average Volume (20 Days) n/a Close	1,217,161

Income Statement

In the last 12 months, Aurinia Pharmaceuticals had revenue of 235.13M and earned 5.75M in profits. Earnings per share was 0.04.

Revenue Revenue n/a Close	235.13M
Gross Profit Gross Profit n/a Close	206.88M
Operating Income Operating Income n/a Close	-4.69M
Net Income Net Income n/a Close	5.75M
EBITDA EBITDA n/a Close	31.73M
EBIT EBIT n/a Close	12.28M
Earnings Per Share (EPS) Earnings Per Share (EPS) n/a Close	0.04

Full Income Statement

Balance Sheet

The company has 83.43M in cash and 79.37M in debt, giving a net cash position of 4.06M.

Cash & Cash Equivalents Cash & Cash Equivalents n/a Close	83.43M
Total Debt Total Debt n/a Close	79.37M
Net Cash Net Cash n/a Close	4.06M
Retained Earnings Retained Earnings n/a Close	-936.57M
Total Assets Total Assets n/a Close	504.85M
Working Capital Working Capital n/a Close	337.36M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 44.39M and capital expenditures -281K, giving a free cash flow of 44.11M.

Operating Cash Flow Operating Cash Flow n/a Close	44.39M
Capital Expenditures Capital Expenditures n/a Close	-281K
Free Cash Flow Free Cash Flow n/a Close	44.11M
FCF Per Share FCF Per Share n/a Close	0.31

Full Cash Flow Statement

Margins

Gross margin is 87.99%, with operating and profit margins of -1.99% and 2.45%.

Gross Margin Gross Margin n/a Close	87.99%
Operating Margin Operating Margin n/a Close	-1.99%
Pretax Margin Pretax Margin n/a Close	3.17%
Profit Margin Profit Margin n/a Close	2.45%
EBITDA Margin EBITDA Margin n/a Close	13.49%
EBIT Margin EBIT Margin n/a Close	-1.99%
FCF Margin FCF Margin n/a Close	18.76%

Dividends & Yields

AUPH does not appear to pay any dividends at this time.

Dividend Per Share Dividend Per Share n/a Close	n/a
Dividend Yield Dividend Yield n/a Close	n/a
Dividend Growth (YoY) Dividend Growth (YoY) n/a Close	n/a
Payout Ratio Payout Ratio n/a Close	n/a
Earnings Yield Earnings Yield n/a Close	0.45%
FCF Yield FCF Yield n/a Close	3.43%

Dividend Details

Analyst Forecast

The average price target for AUPH is $11.5, which is 41.5% higher than the current price. The consensus rating is "Buy".

Price Target Price Target n/a Close	$11.5
Price Target Difference Price Target Difference n/a Close	41.5%
Analyst Consensus Analyst Consensus n/a Close	Buy
Analyst Count Analyst Count n/a Close	2

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value Lynch Fair Value n/a Close	n/a
Lynch Upside Lynch Upside n/a Close	n/a
Graham Number Graham Number n/a Close	1.55
Graham Upside Graham Upside n/a Close	-80.93%

Stock Splits

The last stock split was on Nov 8, 2013. It was a backward split with a ratio of 1:50.

Last Split Date Last Split Date n/a Close	Nov 8, 2013
Split Type Split Type n/a Close	backward
Split Ratio Split Ratio n/a Close	1:50

Scores

Altman Z-Score Altman Z-Score n/a Close	3.2
Piotroski F-Score Piotroski F-Score n/a Close	8